癌症患者的缺血性心脏病
综述指出癌症与缺血性心脏病(IHD)存在多重关联:传统心血管危险因素、低度系统性炎症、意义未明的克隆性造血、治疗相关心血管毒性及社会健康决定因素共同作用。癌症患者IHD表现不典型、出血与缺血风险高、预后更差,血运重建与抗栓决策常需多学科讨论。癌症人群随机对照试验证据非常有限,亟需更多数据指导临床。
要点
- 癌症与IHD共享传统危险因素及低度系统性炎症等机制,可相互促进。
- 癌症患者IHD表现不典型,出血与缺血风险增高,预后较无癌症者更差。
- 血运重建与抗栓治疗决策困难,尤其慢性冠脉综合征,需多学科个体化讨论。
核心结论
- 癌症与缺血性心脏病共存带来重要科学与实践问题,需心脏肿瘤学、心脏病学与肿瘤学界协作应对。
- 癌症患者IHD管理常具挑战性,因表现不典型、出血与缺血风险增加且预后更差。
- 癌症患者随机对照试验证据非常有限,亟需更多数据指导临床实践。
研究设计与样本
- 综述,讨论癌症患者缺血性心脏病的机制、管理挑战与证据缺口。
主要发现
- 传统心血管危险因素如高胆固醇血症和肥胖通过特定机制及低度系统性炎症 predispose 于IHD与癌症。
- 意义未明的克隆性造血可加剧低度系统性炎症。
- 实验研究表明IHD与癌症可相互促进,抗癌治疗的心血管或代谢毒性可导致IHD。
- 社会健康决定因素包括经济稳定、教育与医疗可及性及质量、社区与建筑环境、社会与社区背景,强化IHD与癌症的关联。
临床怎么用
- 癌症患者IHD管理需考虑不典型表现、出血与缺血风险增高及预后更差。
- 血运重建决策与抗栓治疗选择困难,尤其慢性冠脉综合征患者,需多学科讨论兼顾通用指南与个案特征。
局限性
- 癌症患者随机对照试验证据非常有限。
- 亟需更多数据以指导临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiologists are encountering a growing number of cancer patients with ischaemic heart disease (IHD). Several factors account for the interrelationship between these two conditions, in addition to improving survival rates in the cancer population. Established cardiovascular (CV) risk factors, such as hypercholesterolaemia and obesity, predispose to both IHD and cancer, through specific mechanisms and via low-grade, systemic inflammation. This latter is also fuelled by clonal haematopoiesis of indeterminate potential. Furthermore, experimental work indicates that IHD and cancer can promote one another, and the CV or metabolic toxicity of anticancer therapies can lead to IHD. The connections between IHD and cancer are reinforced by social determinants of health, non-medical factors that modify health outcomes and comprise individual and societal domains, including economic stability, educational and healthcare access and quality, neighbourhood and built environment, and social and community context. Management of IHD in cancer patients is often challenging, due to atypical presentation, increased bleeding and ischaemic risk, and worse outcomes as compared to patients without cancer. The decision to proceed with coronary revascularization and the choice of antithrombotic therapy can be difficult, particularly in patients with chronic coronary syndromes, necessitating multidisciplinary discussion that considers both general guidelines and specific features on a case by case basis. Randomized controlled trial evidence in cancer patients is very limited and there is urgent need for more data to inform clinical practice. Therefore, coexistence of IHD and cancer raises important scientific and practical questions that call for collaborative efforts from the cardio-oncology, cardiology, and oncology communities.
引用
- Ameri P, Bertero E, Lombardi M, et al. Ischaemic heart disease in patients with cancer. Eur Heart J. 2024. PMID: 38323638. doi:10.1093/eurheartj/ehae047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。